Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

por Sekiguchi, Naohiro, Kasahara, Senji, Miyamoto, Toshihiro, Kiguchi, Toru, Ohno, Hitoshi, Takagi, Taiga, Tachibana, Masaya, Sumi, Hiroyuki, Kakurai, Yasuyuki, Yamashita, Tomonari, Usuki, Kensuke
Publicado 2022

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer

por Mukai, Hirofumi, Saeki, Toshiaki, Aogi, Kenjiro, Naito, Yoichi, Matsubara, Nobuaki, Shigekawa, Takashi, Ueda, Shigeto, Takashima, Seiki, Hara, Fumikata, Yamashita, Tomonari, Ohwada, Shoichi, Sasaki, Yasutsuna
Publicado 2016

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

por Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru
Publicado 2021